The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes

Sodium–glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise molecular mechanisms are still elusive. We aimed to evaluate the effects of the iSGLT2 empagliflozin on systemic inflammatio...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Med
Auteurs principaux: Iannantuoni, Francesca, M. de Marañon, Aranzazu, Diaz-Morales, Noelia, Falcon, Rosa, Bañuls, Celia, Abad-Jimenez, Zaida, Victor, Victor M., Hernandez-Mijares, Antonio, Rovira-Llopis, Susana
Format: Artigo
Langue:Inglês
Publié: MDPI 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912454/
https://ncbi.nlm.nih.gov/pubmed/31683785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8111814
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires